Nutriband Inc. (NASDAQ: NTRB) has raised approximately $1.75 million through the exercise of 272,671 NTRBW warrants at a strike price of $6.43, according to an announcement by the company. The warrants expired on September 30 without extension, leaving Nutriband with no remaining tradable warrants. The proceeds are earmarked primarily to support the remaining clinical development of AVERSA Fentanyl and the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval.
AVERSA Fentanyl is being developed as a potential first-of-its-kind opioid patch with abuse-deterrent properties. If approved, it could significantly reduce the risk of abuse, misuse, diversion, and accidental exposure associated with fentanyl patches, addressing a critical public health concern. A 2022 Health Advances market analysis estimates peak annual U.S. sales of $80 million to $200 million for the product, underscoring its commercial potential.
The funding comes at a pivotal time as Nutriband advances AVERSA Fentanyl through the regulatory process. The NDA submission is a major milestone for any pharmaceutical company, and the additional capital ensures that Nutriband can complete the necessary clinical work and prepare a robust application. The company’s lead product incorporates its proprietary AVERSA abuse-deterrent technology, which can be applied to any transdermal patch to deter abuse. This technology platform positions Nutriband as a potential leader in the growing market for abuse-deterrent opioid formulations.
For investors, the warrant exercise eliminates a potential overhang and simplifies the company’s capital structure. The fact that warrant holders chose to exercise at $6.43, despite the warrants expiring, suggests confidence in Nutriband’s prospects. The proceeds also reduce the need for additional dilutive financing in the near term, allowing management to focus on execution.
Nutriband’s progress is closely followed by the investment community, and the latest news is available in the company’s newsroom at https://ibn.fm/NTRB. The full press release can be viewed at https://ibn.fm/ZUBic. For more information about Nutriband, visit www.nutriband.com.
MissionIR, a specialized communications platform, assisted in disseminating this announcement. MissionIR is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire, editorial syndication to over 5,000 outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. For more details, visit MissionIR.
